Evelyn Partners Asset Management Ltd Has $9.18 Million Stock Holdings in Waters Corporation $WAT

Evelyn Partners Asset Management Ltd trimmed its holdings in shares of Waters Corporation (NYSE:WAT) by 13.1% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 24,171 shares of the medical instruments supplier’s stock after selling 3,638 shares during the period. Waters makes up about 2.1% of Evelyn Partners Asset Management Ltd’s holdings, making the stock its 13th largest holding. Evelyn Partners Asset Management Ltd’s holdings in Waters were worth $9,181,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of WAT. Brighton Jones LLC lifted its stake in Waters by 112.9% in the 4th quarter. Brighton Jones LLC now owns 1,269 shares of the medical instruments supplier’s stock valued at $471,000 after purchasing an additional 673 shares during the last quarter. Integrated Wealth Concepts LLC lifted its stake in Waters by 2.9% in the 1st quarter. Integrated Wealth Concepts LLC now owns 1,048 shares of the medical instruments supplier’s stock valued at $386,000 after purchasing an additional 30 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in Waters by 3.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 200,051 shares of the medical instruments supplier’s stock valued at $73,733,000 after purchasing an additional 6,976 shares during the last quarter. Empowered Funds LLC lifted its stake in Waters by 16.6% in the 1st quarter. Empowered Funds LLC now owns 1,126 shares of the medical instruments supplier’s stock valued at $415,000 after purchasing an additional 160 shares during the last quarter. Finally, Sivia Capital Partners LLC acquired a new stake in Waters in the 2nd quarter valued at about $232,000. 94.01% of the stock is currently owned by institutional investors and hedge funds.

Waters Trading Down 1.3%

Shares of WAT stock opened at $355.10 on Friday. The firm has a 50 day moving average price of $337.69 and a two-hundred day moving average price of $350.26. The company has a quick ratio of 1.13, a current ratio of 1.79 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $34.87 billion, a PE ratio of 45.12, a price-to-earnings-growth ratio of 2.15 and a beta of 1.21. Waters Corporation has a 12-month low of $275.05 and a 12-month high of $414.15.

Waters (NYSE:WAT) last issued its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $2.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.31 by $0.39. The firm had revenue of $1.27 billion during the quarter, compared to the consensus estimate of $1.20 billion. Waters had a net margin of 11.91% and a return on equity of 15.60%. The business’s revenue for the quarter was up 91.4% compared to the same quarter last year. During the same period last year, the business posted $2.25 earnings per share. Waters has set its Q2 2026 guidance at 2.950-3.050 EPS and its FY 2026 guidance at 14.400-14.600 EPS. As a group, analysts predict that Waters Corporation will post 14.51 earnings per share for the current year.

Wall Street Analyst Weigh In

WAT has been the subject of several recent analyst reports. UBS Group raised their target price on shares of Waters from $330.00 to $375.00 and gave the company a “neutral” rating in a research note on Wednesday, May 6th. The Goldman Sachs Group upgraded shares of Waters to a “strong-buy” rating in a research note on Wednesday, April 1st. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $350.00 target price on shares of Waters in a research note on Thursday, May 7th. HSBC raised their target price on shares of Waters from $415.00 to $435.00 and gave the company a “buy” rating in a research note on Wednesday, June 3rd. Finally, Bank of America raised their price objective on shares of Waters from $370.00 to $400.00 and gave the stock a “neutral” rating in a research report on Tuesday, June 2nd. Three analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $394.56.

Insider Transactions at Waters

In related news, Director Wei Jiang acquired 500 shares of the business’s stock in a transaction on Monday, March 16th. The stock was purchased at an average cost of $289.46 per share, for a total transaction of $144,730.00. Following the completion of the transaction, the director directly owned 3,441 shares of the company’s stock, valued at approximately $996,031.86. The trade was a 17.00% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.31% of the stock is owned by company insiders.

Waters Company Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.